Coronaviruses infections, culminating in the recent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic beginning in 2019, have highlighted the importance of effective vaccines to induce an antibody response with cross-neutralizing activity. COVID-19 vaccines have been rapidly developed to reduce the burden of SARS-CoV-2 infections and disease severity. Cross-protection from seasonal human coronaviruses (hCoVs) infections has been hypothesized but is still controversial. Here, we investigated the neutralizing activity against ancestral SARS-CoV-2 and the variants of concern (VOCs) in individuals vaccinated with two doses of either BNT162b2, mRNA-1273, or AZD1222, with or without a history of SARS-CoV-2 infection. Antibody ...
Summary: SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and ...
Background: Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SAR...
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect agains...
Coronaviruses infections, culminating in the recent severe acute respiratory syndrome coronavirus 2 ...
Coronaviruses infections, culminating in the recent severe acute respiratory syndrome coronavirus 2 ...
Infection-neutralizing antibody responses after SARS-CoV-2 infection or COVID-19 vaccination are an ...
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response an...
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response an...
Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (S...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of nov...
Data de publicació electrònica: 03-09-2021mRNA-based vaccines effectively induce protective neutrali...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve in humans. Spike pr...
The wide spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with phen...
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has now been continuing fo...
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect agains...
Summary: SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and ...
Background: Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SAR...
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect agains...
Coronaviruses infections, culminating in the recent severe acute respiratory syndrome coronavirus 2 ...
Coronaviruses infections, culminating in the recent severe acute respiratory syndrome coronavirus 2 ...
Infection-neutralizing antibody responses after SARS-CoV-2 infection or COVID-19 vaccination are an ...
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response an...
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) antibody neutralization response an...
Understanding vaccine-mediated protection against severe acute respiratory syndrome coronavirus-2 (S...
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of nov...
Data de publicació electrònica: 03-09-2021mRNA-based vaccines effectively induce protective neutrali...
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to evolve in humans. Spike pr...
The wide spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with phen...
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has now been continuing fo...
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect agains...
Summary: SARS-CoV-2 is one of three coronaviruses that have crossed the animal-to-human barrier and ...
Background: Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SAR...
Current SARS-CoV-2 vaccines are losing efficacy against emerging variants and may not protect agains...